INN monograph
Anti-D immunoglobulin
Vaccine / immunological product · POM
Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Kenya market
Wholesale / list prices where loaded
Risk first
Contraindications
- Anaphylaxis to prior dose or component.
- Live vaccines contraindicated in significant immunosuppression and usually pregnancy.
- Defer for moderate–severe acute illness.
Precautions
- Observe 15 minutes post-dose if high anaphylaxis concern.
- Correct injection technique and site.
- Report AEFI via national systems.
Point of care
Dosing
Adult
Full-term Delivery: 300 ug within 72 hrs of delivery (e.g. birth, abortion) if there are no pre-existing anti-D antibodies. (It can still be administered even if a longer period has elapsed). Prophylactic doses of 300ug on 28th and 34th weeks of gestation and 300ug within 72 hrs of delivery for the un-sensitized patients. For transplacental bleed in excess of 4-5ml fetal red cells: administer 60 -75 ug per ml fetal red cells. For stillbirth, abortion, amniocentesis and other sensitizing episodes up to 20 wks gestation: 150 ug per episode within 72 hrs. In case of incompatible blood transfusion: 75 ug / ml of transfused Rh (+ve) blood.
Paediatric
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Renal
N/A generally.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic
N/A generally.
Safety
Drug interactions
- Over 90% of Rh (-ve) women having Rh (+ve) offspring do not form anti-D antibodies.
- As it is not possible to predict who will make antibodies, all Rh(-ve) women with an Rh(+ve) baby must be given prophylaxis.Since Rh antigens are detectable in an embryo a few weeks after conception, anti-D immunoglobulin should also be given to Rh(-ve) women who have aborted.
Safety
Adverse effects
- Local pain, low-grade fever, myalgia.
- Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
Use
Indications
- Therapeutic use is agent- and indication-specific within the class (Vaccine / immunological product).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Prophylaxis of Rhesus sensitization.
Pharmacology
Mode of action
The mechanism of inhibition of anti-body synthesis is unclear, but rapid destruction and clearance of Rh-positive cells from the circulation seem to play a role.
Full mechanism text
The mechanism of inhibition of anti-body synthesis is unclear, but rapid destruction and clearance of Rh-positive cells from the circulation seem to play a role.
ADME
Pharmacokinetics & PD
| Onset | Immune response days–weeks |
|---|---|
| Duration | Months–lifelong (schedule-dependent) |
| Route | IM / SC / ORAL / ID |
Kenya
Brands & prices
| Brand | Company | Pack | KES |
|---|---|---|---|
| Anti-D | Teva Pharmaceuticals | Standard Commercial Pack | — |
| Immunorho | Independent / Registered Supplier | Standard Commercial Pack | — |
| KamRho D | Kamada Ltd | Standard Commercial Pack | — |
| Partobulin | Cream Maple Ltd. | Standard Commercial Pack | — |
| RhoGAM | Independent / Registered Supplier | Standard Commercial Pack | — |
Special populations
Pregnancy & lactation
Pregnancy
Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.
Lactation
Most vaccines compatible; live vaccines usually fine for breastfeeding mother.
Diet
Food & alcohol
- Food
Trust
Sources & disclaimer
Source: Local active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Last reviewed: 01 Aug 2026
Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.